Inderes uses cookies to provide a better user experience and a personalised service. By consenting to the use of cookies, we can develop an even better service and will be able to provide content that is interesting to you.
Medicover operates in the healthcare industry. The company is an international healthcare and diagnostics company and focuses on providing medical services and laboratory analyses. The company's services are aimed at individuals and companies that need fast and accessible care. Medicover was founded in 1994 and is headquartered in Stockholm, Sweden.
* Q3'26 numbers due on 4 November at 07:45 CET * Estimate changes reflect India divestment * Fair value changed to SEK 220-300 (190-270) Q3'26 expectations Overall, we expect Medicover to perform broadly in line with Q2'26. As the Indian (MHI) divestment...
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
* Sells MHI to KKR; deal expected by management to close in Q4* Agreed EV of EUR 1.2bn corresponds to ~46x EV/EBITDA* Improves financial flexibility for European strategy The deal in brief Medicover today announced that it has agreed to divest its Indian...
* Q2 broadly in line across most line items * '26e-'28e adj. EBITDA -0.7%/-0.4%/-0.4% on weaker Romania * FVR unchanged at SEK 190-270 on minor estimate revisions Broadly in line, Romania weighs Revenue grew 7.3% y-o-y to EUR 640m, with org. growth acceleratin...
* -1%/0% adj. EBITDA vs ABGSCe/Infront cons in Q2 * Cons estimates likely unchanged * Trading at 10.2x '26e EV/EBITDA Q2 results: In line with expectations Medicover reported a second quarter in line with cons. Q2 sales were EUR 640m (0% vs ABGSCe, 0...
* Q2'26 numbers due on 22 July at 07:45 CET * Minor estimate changes, margins unchanged * Fair value range kept at SEK 190-270 Q2'26 expectations For Q2, we expect Medicover to perform broadly in line with Q1'26. In Poland and Romania, government funding...
